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Overexpression of group II phospholipase A, in human breast cancer
tissues is closely associated with their malignant potency
S.-I. Yamashita, J.-I. Yamashita & M. Ogawa
Department ofSurgery II, Kumamoto University Medical School, Honjo 1-1-1, Kumamoto 860, Japan.
Summary Membrane-associated phospholipase A2 (M-PLA2) is an enzyme that hydrolyses the sn-2 fatty acyl
ester bond of phosphoglycerides. We measured M-PLA2 concentration in tissue extracts from 325 human
breast cancers using a specific radioimmunoassay recently developed. Correlation analyses between the tissue
concentration of M-PLA2 and clinicopathological factors showed that the enzyme level was significantly higher
in patients with distant metastasis than in those without. In addition, M-PLA2 concentration was significantly
higher in scirrhous carcinoma than in other histological types. No significant association was found between
M-PLA2 concentration and age, menstrual status, tumour size, histological grade, vessel involvement or
oestrogen receptor (ER) and progesterone receptor (PR) status. The expression of M-PLA2 mRNA was
examined in a fibroadenoma, a stage IV breast cancer and its metastatic site of skin. Northern blot analysis
showed a clear hybridisation band corresponding to M-PLA2 mRNA in both primary breast cancer and its
metastatic site, while the fibroadenoma expressed a faint band corresponding to M-PLA2 mRNA. Breast
cancer patients with high M-PLA2 concentrations exhibited significantly shorter disease-free and overall
survival than those with low M-PLA2 concentration at the cut-off point of 5 ng 100 mg-' protein, which was
determined in a separate study. In multivariate analysis, M-PLA2 was found to be an independent prognostic
factor for disease recurrence and death in human breast cancer. The possible significance of M-PLA2
expression in human breast cancer tissue is discussed.
Phospholipase A2 is a lipolytic enzyme that specifically hy-
drolyses the 2-acyl position of a glycerophospholipid (Vadas
& Pruzanski, 1986). There are two structurally different
forms of phospholipase A2 (PLA2): groups I and II (Heinrik-
son et al., 1977; Kanda et al., 1989). Group I PLA2 is often
characterised as the pancreatic type as it is abundant in
pancreatic secretions. Group II PLA2 was initially divided
into two types - membrane-associated PLA2 (M-PLA2) and
secretory PLA2 - but later studies demonstrated that these
two types are identical (Kanda et al., 1989; Seilhamer et al.,
1989). Group I PLA2 has been investigated by many re-
searchers in relation to several diseases, such as acute pan-
creatitis, but little is known about the physiological role of
group II PLA2, despite the presence of this form in a variety
of mammalian cells (van den Bosch, 1980).
Recently, we developed a specific radioimmunoassay for
human M-PLA2 (Matsuda et al., 1991) and reported that the
tissue concentration of M-PLA2 in human breast cancer is
likely to be a prognostic factor (S. Yamashita et al., 1993). In
the previous study including 78 patients (S. Yamashita et al.,
1993), we determined the optimal cut-off point of 50 ng
100mg-' protein according to the method of Tandon et al.
(1990). However, creating a cut-off point for continuous
variables and then using it on the same data set inevitably
leads to optimistic results. Therefore, we have now extended
this study and determined M-PLA2 concentrations in tissue
extracts from another group of 325 patients with breast
cancer, and evaluated the prognostic significance of this
enzyme in human breast cancer using the cut-off point deter-
mined previously (S. Yamashita et al., 1993). In addition, we
have investigated the expression of M-PLA2 mRNA in both
the primary site and metastatic site of human breast cancer.
This study provides evidence for a possible significance of
M-PLA2 expression in the progression of human breast
cancer.
Materials and methods
Patients
The 325 breast cancer patients analysed in this study are
those who underwent curative or non-curative mastectomy in
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the Department of Surgery II, Kumamoto University Hos-
pital, during the 8 year period from 1982 to 1987. The
median follow-up period for patients was 8.2 years (range
5.5-10.7 years). The clinicopathological parameters reviewed
in this study were age, menstrual status, tumour size, number
of positive nodes, presence or absence of distant metastasis,
histological type, histological grade, vessel involvement, oes-
trogen receptor (ER) and progesterone receptor (PR). When
histological typing was performed according to the World
Health Organization (WHO) classification (1981), all
tumours were classified into the same category, i.e. invasive
ductal carcinoma. Therefore, each tumour was further
analysed according to the classification of the Japanese
Breast Cancer Society (1988), and was graded in parallel
according to the criteria described by Bloom and Richardson
(1957), except for 12 comedocarcinomas. ER and PR were
determined by the dextran-coated charcoal method as de-
scribed previously (McGuire et al., 1977). The results of ER
and PR were summarised as negative (<10fmolmg-1 pro-
tein) or positive (>l10fmolmg-1 protein).
Assayfor M-PLA2
Tumour samples were drawn from a pool of frozen speci-
mens (stored at -80C) and each specimen was homogenised
and extracted with 50 mM Tris-HCl buffer (pH 7.4) contain-
ing 0.25% Triton X-100 (Sigma, St Louis, MO, USA) as
described previously (Yamashita et al., 1986). M-PLA2 con-
centration was measured by a radioimmunoassay using anti-
M-PLA2 monoclonal antibody as described by Matsuda et al.
(1991). There is no cross-reactivity of this antibody with
human P-PLA2, pancreatic trypsin, chymotrypsin, elastase 1
and pancreatic secretory trypsin inhibitor (Matsuda et al.,
1991). The purified M-PLA2 was iodinated with [125I]sodium
iodide (New England Nuclear, Boston, MA, USA) by the
chloramine-T method (Hunter & Greenwood, 1962), and the
251I-labelled M-PLA2 was purified by gel filtration on a PD-
10 column (Pharmacia Fine Chemicals, Sweden). Its specific
activity was approximately 3.5 MBqftg '. The detection limit
of M-PLA2 is 7 ng 100 mg-' protein. The intra-assay coeffici-
ent of variation (CV) was obtained by testing one sample on
the same kit ten times. Those for the high, middle and low
sample levels were 3.8, 5.6 and 5.7% respectively. The inter-
assay CV was calculated from assays using the same sample
during a period of 1 month, and those for the three sample
levels were 4.4, 4.5 and 3.2% respectively.
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Northern blot analysis
Total RNA was extracted from a fibroadenoma, a primary
breast cancer and its metastasis to skin by the guanidine
thiocyanate-caesium chloride procedure (Sambrook et al.,
1989). Total RNA (51tg per lane) was separated by 1%
agarose-formaldehyde gels, and transferred to nylon mem-
brane (Hybond N+) by Northern blotting. The blots were
hybridised with 32P-labelled specific probes. The 336 bp
NcoI-ScaI fragment of group II PLA2 cDNA (Seilhamer et
al., 1989) was used for its mRNA detection. Filters were
washed in 0.2 x SSC and 0.1% SDS at 65°C. As a control,
filters were stripped and rehybridised with a radiolabelled
G3PDH probe. The bands were quantitated by a BAS2000
image analyser.
Statistics
The Kruskal-Wallis test was used for the analysis of M-
PLA2 concentration in relation to clinicopathological factors.
The Cox proportional hazards model (Cox, 1972) was used
in multivariate analysis to assess the independent prognostic
significance.
Table I Correlation between M-PLA2 concentration and
clinicopathological factors of human breast cancer
Factor M-PLA2 concentrationa P-value
Age (years)
<50 (143)b 68 21
)50 (182) 54±9 NS
Menstrual status
Pre/perimenopause (168) 72 ± 18
Post-menopause (157) 47 ± 10 NS
Tumour size (cm)
>2 (67) 60± 10
2-5 (203) 52 14 NS
> 5 (55) 89 25
Node involvement
0 (184) 49 7
1-3 (68) 89 21 NS
>4 (73) 61 13
Distant metastasis
Absent (290) 34± 10
Present (35) 273 ± 45 0.025
Histological type
Papillotubular (75) 21 ± 6
Solid tubular (120) 36 ± 12
Scirrhous (114) 116 24 0.016
Others (16) 24 ± 3
Histological gradec
Grade I (88) 46 11
Grade II (122) 68 ± 13 NS
Grade III (103) 69 ± 13
Vessel involvement
Absent (207) 55 ± 22
Present (118) 69 15 NS
ER
Positive (163) 62 ± 12
Negative (128) 50 ± 17 NS
Unknown (34) 88 ± 27
PR
Positive (99) 71 ± 30
Negative (184) 49 ± 15 NS
Unknown (42) 83 ± 26
aMean ± s.e. bNumbers in parentheses are the number of patients.
cTwelve comedocarcinomas were excluded from this analysis. NS,
not significant.
Results
Relation between M-PLA2 concentration and
clinicopathologicalfactors
M-PLA2 was detected in tissue extracts from 311 of 325
specimens, the concentration ranging from 7.3 to 1,755 ng
100 mg-' protein. The median value of M-PLA2 concentra-
tion was 52 ng 100 mg-' protein. Table I shows the correla-
tion between M-PLA2 concentration and the characteristics
of the patients. When M-PLA2 concentration was compared
in terms of age, menstrual status, tumour size, nodal status,
histological grade, vessel involvement, ER and PR, no
significant association was found between M-PLA2 concen-
tration and any of these features. However, M-PLA2 concen-
tration was significantly higher in scirrhous carcinoma than
in other histological types (P = 0.016). Similarly, M-PLA2
concentration was significantly higher in distant metastatsis-
positive than in -negative patients (P = 0.025).
Relation between M-PLA2 concentration and survival
To evaluate the prognostic significance of M-PLA2, we
analysed disease-free survival and overall survival in 290
breast cancer patients. Thirty-five patients with distant
metastases at the time of primary therapy were excluded
from this analysis. The cut-off point of 50 ng 100 mg-' pro-
tein was used because our previous study of another group of
patients demonstrated that this cut-off point could give a
statistically significant separation for risk of relapse accord-
ing to the method of Tandon et al. (1990). This cut-off point
is close to the median value (52 ng 100 mg- protein) of the
present series. As shown in Figure 1, patients with breast
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Figure 1 Disease-free and overall survival curves in 290 breast
cancer patients having no distant metastasis according to M-
PLA2 concentration in tumour extracts. The cut-off point
between high and low enzyme level was 50 ng 100mg-' protein.
Number of paitents in each group: high M-PLA2, 133; low
M-PLA2, 157.1168 S.-I. YAMASHITA et al.
cancer tissue containing a high concentration of M-PLA2 had
a significantly shorter disease-free survival (P = 0.008) and
overall survival (P = 0.011) time than those with a low con-
tent of the enzyme. In multivariate analysis including all
variables, M-PLA2 was found to be an independent prognos-
tic factor for recurrence and for death of about the same
import as lymph node involvement (Tables II and III).
M-PLA2 mRNA expression
Northern blot analysis of total RNA from one fibro-
adenoma, one stage IV breast carcinoma and its skin metas-
tasis is shown in Figure 2. Using a radiolabelled M-PLA2
cDNA probe (336 bp NcoI-ScaI fragment), M-PLA2 mRNA
was clearly demonstrated in total RNA preparations from
breast carcinoma and its metastasis site, while fibroadenoma
expressed only a faintly hybridising band of M-PLA2
mRNA. Interestingly, the metastasis site expressed more
M-PLA2 mRNA than the primary tumour.
Discussion
We and other investigators have demonstrated that a tran-
sient increase in serum M-PLA2 concentration is observed
during surgery (Matsuda et al., 1991) and in various clinical
conditions such as endotoxic shock (Vadas & Hay, 1983) and
multiple injuries (Uhl et al., 1990), suggesting that this
enzyme is one of the acute-phase reactants. We also showed
that serum M-PLA2 concentration was significantly elevated
in patients with various malignant tumours (Matsuda et al.,
1991). Since the incidence and magnitude of the elevation
were greater in patients with advanced breast cancers than in
those with early stages, we speculated that this enzyme might
be produced by breast cancer cells themselves.
Immunohistochemical study showed that M-PLA2 was pre-
ferentially stained in breast cancer cells rather than breast
stromal cells (Yamashita et al., 1993), indicating that breast
cancer cells produce a large amount of this enzyme.
In the present study, correlation analyses showed that
tissue M-PLA2 level was significantly higher in distant
metastasis-positive than in -negative patients. Furthermore,
of interest was the finding that the distant metastasis from a
stage IV carcinoma showed even larger amounts of M-PLA2
mRNA than the primary tumour. These results suggest that
the expression of this enzyme may be related to the meta-
static potency of human breast cancer.
Histologically scirrhous carcinoma, which is characterised
by its prominent stromal cellularity, was also related to high
M-PLA2 concentrations in tissue extracts. In our previous
report, the intensity of immunohistochemical staining was
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Figure 2 Northern blot analysis of total RNA from a
fibroadenoma, a primary breast cancer and its metastasis to skin.
Total RNA was hybridised with cDNA from human group II
PLA2 as probe. To assess equal load ofmRNA per lane, the filter
was subsequently hybridised to a G3PDH probe. 28S and 18S
rRNA bands were used as molecular weight markers.
M-PLA2
Table II M-PLA2 and clinicopathological parameters as prognostic factors for relapse in
290 stage I-III breast cancer patients
Univariate analyses Multivariate analyses
Parameters Relative risk P-value Relative risk P-value
Independently associated with relapse
Nodal status
0 1.0 1.0
1-3 2.2 0.001 1.7 0.001
)4 4.1 2.9
M-PLA2 concentration
<50 1.0 1.0
50 3.3 0.008 2.7 0.015
Associated with relapse only when evaluated alone
Tumour size (cm)
<2 1.0
2-5 1.5
> 5 2.7 0.024 NS
Histological grade
Grade I 1.0
Grade II 1.7
Grade III 3.0 0.015 NS
Vessel involvement
Absent 1.0
Present 2.0 0.050 NS
Not associated with relapse
Age NS NS
Menstrual status NS NS
Histological type NS NS
ER NS NS
PR NS NS
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Table III M-PLA2 and clinicopathological parameters as prognostic factors for deeath in
290 stage 1-111 breast cancer patients
Univariate analyses Multivariate analyses
Parameters Relative risk P-value Relative risk P-value
Independently associated with survival
Nodal status
0 1.0 1.0
1-3 2.1 0.001 1.6 0.001
>4 3.6 2.5
M-PLA2 concentration
<50 1.0 1.0
50 3.5 0.011 2.5 0.022
Associated with survival only when evaluated alone
Tumour size (cm)
<2 1.0
2-5 1.1
>5 1.9 0.034 NS
Histological grade
Grade I 1.0
Grade II 1.2
Grade III 2.9 0.030 NS
Vessel involvement
Absent 1.0
Present 1.5 0.048 NS
PR
Positive 1.0
Negative 1.4 0.044 NS
Not associated with survival
Age NS NS
Menstrual status NS NS
Histological type NS NS
ER NS NS
NS, not significant.
greater in scirrhous carcinoma than in other histological
types (S. Yamashita et al., 1993). Immunohistochemically
M-PLA2-positive cells were localised at the invading edge of
the tumour where cancer cells were in contact with surround-
ing non-neoplastic tissues (S. Yamashita et al., 1993). Recent-
ly, we found that human M-PLA2 itself has a mitogenic effect
on fibroblasts (Kurizaki et al., 1992). In addition, M-PLA2
augments the production of prostaglandin E2 (PGE2), which
is known to stimulate mitogenesis in fibroblasts (Nolan et al.,
1988; Hara et al., 1991). These findings suggest that M-PLA2
may play an important role in stimulating the growth of
stromal cells in breast cancer tissues in a paracrine fashion.
Further, PGE2 released at the tumour site inhibits the host
immunological response and enhances tumour growth (Balch
et al., 1984; Okada et al., 1990). The release of fatty acids is
at least two orders of magnitude greater than eicosanoid
production, and these fatty acids also have many direct
biological effects on normal and malignant cells (Imagawa et
al., 1989; Clerc et al., 1991).
Reliable predictors of survival or relapse in patients with
breast cancer aid in determining the use of adjuvant
chemotherapy or endocrine therapy. Established prognostic
indicators, such as age, lymph node involvement, tumour
grade and hormone receptor status, assist in predicting
patient outcome or response to treatment, but are not
entirely dependable. Several enzymes determined in the
cytoplasm and organelles of tumour cells have been found to
have prognostic value in human breast cancer. Most of these
enzymes are proteinases, such as plasminogen activator
(Janicke et al., 1989; Duffy et al., 1990; J. Yamashita et al.,
1993) and cathepsin D (Spyratos et al., 1989; Tandon et al.,
1990), which have been implicated in tumour infiltration and
metastasis. The present study offers statistical evidence that
M-PLA2 concentration in tissue extracts is an independent
prognostic factor that clearly identifies high- and low-risk
patients using a cut-off point determined previously. To our
knowledge, this is the first lipolytic enzyme which can be
added to the list of second-generation prognostic factors in
human breast cancer.
In conclusion, the present study provides evidence that
M-PLA2 expression is closely associated with the malignant
potential of human breast cancer and that this new biological
factor can be an independent prognostic factor.
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